CODX · XBRL financial data

Co-Diagnostics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CODX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	74,553	97,886	34,218	6,812	3,915	622
Cost of revenue	16,591	11,575	5,481	4,185	999	222
Gross profit	57,961	86,311	28,737	2,627	2,916	400
Research and development	3,185	14,962	17,438	22,963	20,980	19,137
General and administrative	8,279	11,551	14,263	14,279	16,157	9,058
Total operating expenses	16,268	40,246	55,717	45,333	42,997	50,565
Operating income (loss)	41,694	46,065	(26,980)	(42,706)	(40,081)	(50,165)
Income tax expense (benefit)	91	8,977	(4,609)	(2,778)	57	(1,616)
Net income (loss)	42,479	36,659	(14,238)	(35,333)	(37,639)	(46,896)
Earnings per share, basic USD per share	1.59	1.27	(0.45)	(1.20)	(1.24)	(35.25)
Earnings per share, diluted USD per share	1.52	1.23	(0.45)	(1.20)	(1.24)	(35.25)
Weighted average shares, basic thousands of shares	26,720	28,875	31,479	29,347	30,335	1,330
Weighted average shares, diluted thousands of shares	28,000	29,904	31,479	29,347	30,335	1,330

Fiscal years (CODX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	42,977	88,607	22,974	14,917	2,937	11,885
Marketable securities	4,335	1,255	58,289	43,632	26,811	—
Accounts receivable	12,137	20,839	3,454	304	133	190
Inventory	7,995	2,004	5,310	1,665	1,073	992
Prepaid and other current assets	—	2,338	761	1,597	1,339	582
Total current assets	68,360	115,119	92,734	62,141	32,292	13,693
Property and equipment, net	950	1,933	2,539	3,036	2,761	2,272
Right-of-use asset	—	—	372	2,967	2,115	1,207
Goodwill	—	14,707	—	—	—	—
Total assets	71,237	160,034	123,086	95,321	64,000	24,743
Accounts payable	598	608	952	1,482	3,294	1,878
Accrued liabilities	3,487	3,860	934	2,173	2,562	865
Total current liabilities	4,511	12,598	3,873	5,748	7,316	3,540
Lease liability, non-current	—	—	51	2,152	1,237	574
Total liabilities	4,541	25,559	8,566	9,307	9,688	4,114
Retained earnings (accumulated deficit)	17,511	54,169	39,931	4,598	(33,041)	(80,374)
Total stockholders' equity	66,697	134,475	114,520	86,014	54,312	20,629
Total liabilities and equity	71,237	160,034	123,086	95,321	64,000	24,743
Common shares outstanding (cover page) thousands of shares	28,666	33,965	30,923	31,260	33,573	3,602

Fiscal years (CODX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	42,479	36,659	(14,238)	(35,333)	(37,639)	(46,896)
Stock-based compensation	2,738	5,509	7,543	8,337	5,435	2,248
Depreciation and amortization	139	335	1,283	1,230	1,377	—
Net cash from operating activities	28,165	41,081	6,569	(22,082)	(29,155)	(29,137)
Purchases of property and equipment	774	669	1,428	1,365	748	700
Net cash from investing activities	(5,824)	4,099	(58,168)	15,389	17,071	26,273
Proceeds from issuing common stock	19,470	450	178	—	—	—
Share repurchases	—	—	14,212	1,364	—	—
Net cash from financing activities	19,743	450	(14,034)	(1,364)	104	11,812
Net change in cash	42,084	45,631	(65,633)	(8,057)	(11,980)	8,948

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Co-Diagnostics	3,650	166	(7,153)*	6.3M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Lifeward	9,448	6,623	(6,005)*	2.8M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V	18	not reported	(79)*	2.9M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Guided Therapeutics	12	0	(319)*	96.5M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Medinotec	2,584	3,201	108*	11.8M	—	Q2 FY27 10-QAug 31, 2026
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.